Haleon
About: Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
Employees: 24,622
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
86% more first-time investments, than exits
New positions opened: 82 | Existing positions closed: 44
21% more repeat investments, than reductions
Existing positions increased: 213 | Existing positions reduced: 176
6.51% more ownership
Funds ownership: 6.3% [Q1] → 12.81% (+6.51%) [Q2]
4% more funds holding
Funds holding: 590 [Q1] → 613 (+23) [Q2]
2% more capital invested
Capital invested by funds: $5.86B [Q1] → $5.97B (+$113M) [Q2]
33% less funds holding in top 10
Funds holding in top 10: 3 [Q1] → 2 (-1) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for HLN.
Financial journalist opinion
Based on 4 articles about HLN published over the past 30 days
